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1. Introduction 
Focal cortical dysplasias (FCDs), initially thought to be rare, are a common cause of drug-
refractory epilepsy in both children and adults. Successful resection and subsequent 
characterization of FCDs was first described by Taylor et al. in 1971 from pathological 
specimens obtained in patients treated for intractable temporal lobe epilepsy (Tassi, et 
al.,2001; Becker, et al.,2002; Tassi, et al.,2002; Urbach, et al.,2002; Nobili, et al.,2009). The 
dysplasias include abnormalities of cellular proliferation, migration, and differentiation. 
From recent published reports, patients with cortical dysplasia constitute approximately 
14% of all patients undergoing epilepsy neurosurgery. Cortical dysplasia is the most 
common etiology in younger surgical patients. Using the UCLA cohort as an example, 
cortical dysplasia was the histopathologic substrate identified in 75% of infants and children 
operated in the first 2 years of life. By comparison, cortical dysplasia was found in less than 
10% in those having surgery who were older than age 21 years (Diaz, et al., 2008).  
Surgical evaluation and treatment of FCDs requires an understanding of pathological, 
presurgical imaging, EEG findings and intraoperative mapping of epileptogenic zone and 
functional areas (Sisodiya,2011). 
2. Histopathological characteristics of FCD 
The establishment of a uniform terminology and classification of histopathological findings 
associated with FCDs has recently been proposed by a consensus panel of 
neuropathologists, neuroepileptologists, and neuroradiologists. 
The Palmini classification has been adopted most widely to categorize these heterogeneous 
lesions. Palmini et al. determined that several distinct histopathological features of the 
cortex must be present for a lesion to be considered a true FCD. These include architectural 
abnormalities, either dyslamination or columnar disorganization with or without 
dysmorphic neurons, giant cells, or balloon cells. Palmini et al. described 2 major types and 
4 subtypes of FCD: Type 1 dysplasia refers to the most subtle alterations in cortical 
lamination and ectopic neurons in the white matter or immediately adjacent to layer 1. 1a 
with isolated architectural abnormalities alone; Type 1b, including giant neurons; Whereas 
type 2 dysplasia refers to areas of more extensive dyslamination outside of layer 1 with the 
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absence (type 2a) or presence (type 2b) of cytomegalic or balloon cells (Crino,2009; 
Gumbinger, et al.,2009; Nobili, et al.,2009; Wong,2009; Kim, et al.,2010; Krsek, et al.,2010). 
(Table 1) 
 
Type Subtype Pathology features 
1a Architectural cortical abnormalities ±feature of mild MCD FCD type 1 
1b Architectural abnormalities and giant or immature neurons 
2a Architectural abnormalities with dysmorphic neurons but no 
balloon cells 
FCD type 1 
2b Architectural abnormalities with dysmorphic neurons and 
balloon cells 
Table 1. Pathological features of FCD subtypes as outlined in the system by Palmini et 
al.(2004) 
Macroscopic abnormalities may be present in surgical resections from FCD cases. There may 
be apparent thickening of the cortical gray matter, blurring of the gray-white border and the 
tissue may appear firmer (Figure 1). The overall lesion size varies and can be up to several 
centimetres broad, involving both sulci and gyri. On histological examination, abnormalities 
of cortical laminar architecture (also called ‘dyslamination’) are common to all types of FCD 
with loss of distinction between cortical layers, more easily visualized with Nissl stain or 
NeuN immunohistochemistry(Crino,2009; Gumbinger, et al.,2009; Nobili, et al.,2009; 
Wong,2009; Krsek, et al.,2010; Wong,2010).  
Patients with mild Palmini type 1 CD represent about 50% of the surgical cases, and these 
lesions tend to occur most often in the temporal lobe, often associated with hippocampal 
sclerosis. By comparison, patients with severe type 2 CD present at younger ages, often with 
multilobar extratemporal lesions, and more aggressive seizures(Morales, et al.,2009; 
Blumcke, et al.,2011; Palmini,2011).  
Although strictly a pathological classification, an expected correlation with neuroimaging 
results was summarized within the classification system. Mild MCDs and Type 1a and 1b 
FCDs were not considered likely to have correlating characteristics on MR images, unlike 
Type II which would probably exhibit changes including increased cortical thickness, 
blurring of grey–white junction, and extension of cortical tissue toward the ventricle. 
The etiology of these lesions is poorly understood, and has been postulated to be due to 
possible in utero focal insults to cortex or to genetic mutations responsible for disordered cell 
proliferation or differentiation. Tuberous sclerosis complex (TSC) represents a more specific 
form of type 2b FCD, with the presence of areas of dysplasia containing giant cytomegalic cells 
as well as dysplastic neurons and astrocytes, termed ‘‘tubers.’’ TSC1 and TSC2 are the genes 
that are found to be mutated in TSC, and encode for hamartin and tuberin, 
respectively(Lugnier, et al.,2009; Wong,2010). Hamartin and tuberin cooperatively inhibit 
excessive protein translation by acting to down-regulate the mammalian target of rapamycin 
(mTOR). The mTOR pathway has been shown to be upregulated in TSC, and some of its 
components are also overactive in non-TSC FCDs, suggesting that this pathway may be 
common to a wide range of cortical dysplasias(Crino,2009; Gumbinger, et al.,2009; Nobili, et 
al.,2009; Wong,2009; Krsek, et al.,2010; Wong,2010; Blumcke, et al.,2011; Palmini,2011). 
The epileptogenicity of FCDs is hypothesized to be caused by abnormal synaptogenesis and 
dysregulated gaminobutyric acid-mediated inhibitory signalling. Enhanced neuronal 
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hyperexcitability may also play a role in the abnormal synchronization of neuronal 
populations, leading to prolonged trains of epileptic activity (Sisodiya, et al.,2009). 
3. Preoperative evaluation 
The presurgical evaluation for pharmacoresistant patients with cortical dysplasia is often 
challenging. There is no particular seizure semiology that characterizes patients with cortical 
dysplasia from other epilepsy surgery patients with lesions in different locations within the 
brain. Furthermore, there are no distinctive interictal or ictal scalp EEG ‘‘signatures’’ that are 
exclusively associated with cortical dysplasia in patients with refractory epilepsy. No one 
single test of the presurgical evaluation in CD patients is 100% accurate. Based on 
retrospective cohort studies, the accuracy of investigations are: interictal scalp EEG, 50%; 
ictal scalp EEG, 65%; MR), 66%; FDG-PET, 81%; and ictal SPECT, 57%.  Combined 
evaluation of detailed history and physical examination, EEG, MRI and other functional 
Neuroimaging plays a vital role in presurgical planning in patients with intractable epilepsy 
(Duchowny,2009; Gumbinger, et al.,2009; Roper,2009; Sisodiya, et al.,2009).  
3.1 Clinical findings 
The preoperative evaluation in a patient with medically refractory seizure starts with a 
detailed history and physical examination. Seizure type may provide information about the 
location of the epileptogenic zone, and can contribute to the prognosis of seizure control 
after resection. Neurological deficits identified on physical examination may point to the 
area of cortex most affected and provide clues as to the focal, multifocal, or diffuse nature of 
the underlying pathological entity (Goldring,1987; Crino,2009; Nobili, et al.,2009; Sisodiya, 
et al.,2009; Tassi, et al.,2009; Kim, et al.,2010).  
3.2 EEG 
Patients with medically intractable seizures should undergo preoperative evaluation with 
video-assisted scalp EEG to correlate ictal EEG graphic events with the seizure semiology. 
The ictal onset zone is defined as the region showing focal rhythmic activity, bursts of high-
frequency discharges, repetitive spiking, or electrodecremental patterns(Jiang, et al.,2010). 
The disadvantage of scalp EEG is that in patients with FCDs there is a high incidence of 
widespread interictal spiking, which may obscure identification of the epileptogenic zone. 
Interictal and ictal EEG findings often poorly localize to the MRI-identified lesion in patients 
with cortical dysplasia. Interictal findings localize on scalp EEG to the eventual area of 
resection in 48%, and ictal findings localize to one area in 68% of epilepsy surgery patients 
with cortical dysplasia (Francione, et al.,2003; Aubert, et al.,2009; LeVan, et al.,2010).  
3.3 MRI 
Identifying a focal lesion on MRI in patients with medically refractory epilepsy remains one 
of the most important factors in determining surgical outcomes. Therefore, there has been 
ongoing interest in utilizing new technologies to improve the rate of detection and thereby 
improve surgical outcomes. Although a number of lesions can result in epilepsy, FCDs 
remain the most difficult to detect. With new high-field and multichannel technology, the 
maximum gains in signal to noise are at the cortical surface, making patients with focal-
onset refractory epilepsy the most likely to benefit from these technical advances 
(Bernasconi, et al.,2011; Kim, et al.,2011).  
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Patients with medically intractable epilepsy should undergo MR imaging in 3 planes for 
best characterization of the potential underlying FCD. If a temporal lobe lesion is suspected, 
preoperative MR imaging should include T1-weighted sagittal studies, coronal MPRAGE, 
coronal FLAIR, and fast T2-weighted coronal sequences. Preoperative MR images obtained 
in patients with a suspected extratemporal lesion consists of axial fast FLAIR, fastT2-
weighted axial, T1-weighted sagittal, and coronal MPRAGE MR imaging sequences. 
Imaging findings of CDs include thickening of the cortex, blurring of the gray–white matter 
junction, abnormal cortical signal and increased T2/FLAIR (fluid-attenuated inversion 
recovery) and/or T1 hypointense signal extending from the ependymal surface to the 
cortical surface. Additional imaging features that have been described include focal 
hypoplasia, a deep sulcus with malformations at the depths of the sulci, broadening of the 
gyri, and white matter atrophy. Many of these features can be seen on both T1- and T2-
weighted images, although the CD for a given patient maybe more apparent on any one of 
these imaging sequences. FLAIR, especially volumetric FLAIR at 3T, is very sensitive for 
identifying white matter involvement (Figure 1). There has been ongoing interest in utilizing 
new advanced MRI techniques to improve the ability to identify, diagnose, characterize, and 
delineate cortical dysplasias. Technologic gains such as multichannel coils(32 phased array 
and beyond) and higher field strengths (3T, 7T, and greater) coupled with newer imaging 
sequences such as arterial spin labeling (ASL), susceptibility weighted imaging(SWI) and 
diffusion tensor/spectrum imaging(DTI/DSI) are likely to increase yield(Diehl, et al.,2010).  
To improve diagnostic accuracy, automated techniques are being developed that identify 
areas for closer scrutiny by an experienced neuroradiologist. One method for automated 
lesion detection is voxel-based morphometry. This technique employs the statistical 
parametric mapping techniques developed for functional MRI to allow voxel-based 
comparisons between patients and a cohort of control subjects with the goal of identifying 
areas of the brain that may be different in volume, signal intensity, texture, or sharpness of 
boundaries. However, in voxel-based morphometry it is difficult to interpret positive 
results, as differences in image intensity can occur due to differences in gyral folding, 
differences in relative cortical gray-to-white matter volume, incorrect segmentation, or other 
factors. Similarly, false-negative findings can be caused by the blurring of gray-white matter 
boundaries, which results when control groups are averaged (Chiang, et al.,2009; Rajan, et 
al.,2009). 
3.4 MEG 
In patients with seizures, MEG is usually most useful in patients with interictal activity, as 
ictal events are often associated with motion artifact. MEG and EEG appear to have similar 
sensitivity to record interictal events, with MEG and EEG often providing complementary 
data. In up to one-third of EEG-negative patients, MEG can be expected to detect interictal 
epileptiform activity and is particularly effective in neocortical epilepsy and FCDs 
(Andrade,2009; Beleza,2009; Fauser, et al.,2009) . 
3.5 Other functional imaging 
With patients presenting with nonlocalized scalp EEG and subtle or normal MRI scans, 
many centers incorporated additional functional and neuroimaging studies into the 
multimodality presurgical evaluation to increase the detection of patients with cortical 
dysplasia. Of these tools, FDG-PET has been shown to be one of the more sensitive 
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techniques in identifying areas of cortical dysplasia. Contemporary studies indicate that 
FDG-PET detects interictal hypometabolism that localized to areas of cortical dysplasia in 
approximately 81% of patients. By comparison, 57%  of cortical dysplasia patients have 
localized ictal SPECT scans. For both FDG-PET and ictal SPECT, some patients with normal 
MRI show positive scans. Hence, adjunctive neuroimaging methods, such as FDG-PET, ictal 
SPECT, and MEG, have an important role in the presurgical evaluation of patients with 
cortical dysplasia (Fedi, et al.,2003; Chassoux, et al.,2010; Phi, et al.,2010). 
 
 
Fig. 1. The T1 weighted MRI(A), macroscopic findings(B)  and microscopic findings with H 
& E stain (C ) and in-situ immunohistochemistry with NeuN 
4. Surgical considerations 
The goal of clinical, EEG, and neuroimaging preoperative assessment is to identify the 
cortical area producing seizures and generating discharges and its anatomical and 
functional relationships. Concordance amongst the different modalities used to identify the 
lesion producing seizures is critical for surgical planning. Preoperative understanding of the 
epileptogenic zone, surrounding, or encompassing functional cortex, and the characteristic 
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vascularization of the area in individual patients provides a map for planning the surgical 
approach, the limits of excision, and determining the potential risk to function(Diaz, et 
al.,2008).  
The purpose of surgical intervention in the management intractable epilepsy with 
underlying histological evidence of cortical dysplasia is to improve seizure control and 
maximize the potential for normal neuropsychological development. The surgical approach 
to FCD is dependent on the presence of a lesion visible on MR imaging, its location to 
eloquent cortex, and the concordance of presurgical EEG and functional neuroimaging with 
identifiable lesions. If a well-defined lesion is visible on MR imaging that correlates with 
EEG localization of the epileptogenic focus, resection may be performed in a single-stage 
procedure with intraoperative electrocorticography as a guide. If no lesion is visible on MR 
images or if it is localized within eloquent cortex based on the results of noninvasive 
preoperative studies, a 2-stage procedure with invasive EEG monitoring should be 
considered for the purpose of locaizing the primary and secondary ictal epileptogenic zones, 
irritative zones, and cortical mapping of eloquent cortex to guide the focal cortical resection.  
Once the epileptogenic zone is identified, different surgical strategies can be used: 
lesionectomy, focal cortical resections, or regional or hemispheric surgical disconnection. 
En-bloc resection between cortical vessels, sparing as many vessels as possible to avoid local 
arterial or venous infarction is essential. An important reason for incomplete resection is the 
intentional avoidance of the eloquent cortex. Intraoperative corticography or invasive EEG 
monitoring prior to extension of resection may be considered if the lesion is not well defined 
on preoperative neuroimaging or noninvasive EEG studies. The extent of further surgery 
after a first procedure is often limited by the proximity of the remnant epileptogenic zone to 
the functional cortex. Subsequently, there is a greater risk of neurological impairments such 
as paresis or visual field deficits after repeated surgery, depending on the location of the 
surgical target. Mapping studies of epilepsy surgical patients reveals a close association 
between dysplastic tissue, the epileptogenic zone, and eloquent cortical function. Seizure 
onset commonly occurs within or near cortical areas for language, motor function, or vision.  
Structural and functional overlap is frequent in FCD(Goldring,1987; Diaz, et al.,2008; 
Crino,2009; Duchowny,2009; Roper,2009; Kim, et al.,2010).  
Invasive video-EEG monitoring with subdural grids or depth electrodes may be indicated to 
aid in localization of the epileptogenic zone particularly in patients with cryptogenic lesions 
on MR imaging, lesions located in or near eloquent cortex, or evidence of bilateral or 
multifocal seizure onset as determined by scalp video-EEG. Subdural electrodes allow 
extraoperative mapping of the eloquent cortex including critical somatosensory, motor, and 
language areas. These techniques can be used on any patient, but may be more important in 
children in whom intraoperative cortical mapping is impossible. This technique provides 
important information about the function and spatial relationship of the epileptogenic zone 
to functional cortex (Goldring,1987; Crino,2009; Duchowny,2009; Roper,2009; Kim, et 
al.,2010).  
5. Seizure outcome after surgery  
Contemporary series report that 62% of patients with CD are seizure free after resective 
neurosurgery, with higher rates for complete (77%) compared with incomplete (20%) 
removal of the lesion. Temporal location of FCDs lesions is associated with an 87% rate of 
freedom from seizures. Negative prognostic factors include long duration of epilepsy before 
www.intechopen.com
 Surgical Treatment of Intractable Epilepsy Associated with Focal Cortical Dysplasia 
 
317 
surgery, older age at surgery, multiple seizure types, the occurrence of secondary 
generalized seizures after surgery, the need for invasive EEG recording, and incomplete 
resection of the epileptogenic area. In a series of patients who underwent frontal lobectomy 
for frontal lobe epilepsy, independent predictors of seizure recurrence were no MCD/FCD 
found on MRI, extrafrontal MR imaging abnormalities, generalized ictal EEG patterns, acute 
postoperative seizures, and incomplete resection. When no lesion was visible on pre-
operative MR images, only 37% of adults and children were seizure-free 1 year 
postoperatively. Positive prognostic factors for good seizure control include the presence of 
local epileptogenic discharges, a well-defined lesion on preoperative MR images, and 
coincidence of ictal SPECT findings with the resection site. The completeness of resection 
appears to have the most predictive power for long-term seizure-free outcome.Surgical 
failure, defined as the presence of persistent or recurrent seizure activity, is highly 
dependent on the completeness of resection of the epileptogenic cortex. Intra-operative 
challenges to complete resection include poorly defined epileptogenic zone margins on 
neuroimaging or EEG, the presence of important vascular structures in the epileptogenic 
zone, proximity of the epileptogenic zone to eloquent cortex, or an epileptogenic zone that 
has important cortical function. It is important to understand that epileptic foci and 
underlying cortical dysplasia may occur outside of the clearly delineated areas of 
abnormality demonstrated on MR imaging (Diaz, et al.,2008).  
Morbidity (<3%) and mortality (0.2%) are low for patients with CD undergoing epilepsy 
neurosurgery. The rate of transient postoperative complications after cortical resection, 
lobectomy, or hemispherectomy for cortical dysplasia has been reported as 10.9%. 
Significant permanent neurological deficits are rare, but initial neurological deterioration 
(for example hemiparesis, dysphasia, dysnomia, and/or memory disturbance) is very 
common in a high proportion of cases(Krsek, et al.,2010; Phi, et al.,2010; Tassi, et al.,2010). 
6. Challenges and future directions 
Future challenges include the noninvasive identification of patients with CD with 100% 
accuracy, evaluation of long-term out comes in surgical patients, and devising new treatments 
based on a better understanding of the neurobiology leading to seizures in CD tissue. 
6.1 Identify refractory epilepsy patients with cortical dysplasia with 100% accuracy 
A substantial proportion of epilepsy surgery patients with cortical dysplasia have non 
localizing foci using scalp EEG and ‘‘normal’’ MRI scans. Many of these are patients have 
mild cortical dysplasia. Thus how many patients with cortical dysplasia are we missing 
using current presurgical protocols that rely on structural MRI scans? We need more precise 
presurgical protocols and technologies that can screen patients with refractory epilepsy 
noninvasively for the presence of subtle cortical dysplasia (Bernasconi, et al., 2011; Kim, et 
al., 2011). 
6.2 Determine the long-term outcomes for epilepsy surgery patients with mild and 
severe cortical dysplasia 
At present, there appear to be minimal differences for patients with type 1 and type 2 
cortical dysplasia in the percentage of patient’s seizure free 1–2 years after surgery, if the 
lesion is completely removed. However, it is unclear if patients remain seizure free many 
years after surgery. In addition, we do not know if patients have long-term improvements in 
www.intechopen.com
 Novel Treatment of Epilepsy 
 
318 
assessments of quality of life and psychosocial outcomes. Hence, long-term outcome studies 
are needed to determine if there are differences in the percentage of patients who are seizure 
free along with developmental and psychosocial results, for patients with mild and severe 
cortical dysplasia (Diaz, et al.,2008). 
6.3 Devise new and improved treatments for drug-refractory epilepsy patients with 
cortical dysplasia 
A proportion of medically refractory patients with cortical dysplasia are poor surgical 
candidates because the lesion cannot be completely removed if it involves areas of 
important functional cortex. A future challenge will be to develop new therapies that control 
seizures so that more patients with cortical dysplasia can be treated successfully without 
increasing the risk of new neurologic deficits. This may involve remedies based on 
mechanisms learned from the basic science laboratory involving abnormal cells and circuits 
in cortical dysplasia tissue. These therapies will also need to include emerging knowledge of 
the genetic abnormalities that may be different in patients with mild and severe cortical 
dysplasia. Hence, there is a need for more research to understand mechanisms of 
epileptogenesis and pathogenesis along with genetics in patients with cortical dysplasia, 
and whether these mechanisms are different in those with mild and severe disease. The use 
of human tissue may be an important research opportunity for patients with cortical 
dysplasia, as it offers the opportunity to try new pharmacologic treatments on this disease. 
In the future, we hope to understand more about the clinical characteristics and mechanisms 
of epileptogenesis in patients with mild and severe cortical dysplasia that can be translated 
into novel therapies(Beleza,2009; Crino,2009; Duchowny,2009; Roper,2009). 
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